Latest update provided to us by Scholar Rock
Late last month, SMA United reached out to Scholar Rock regarding their trials involving SRK-015 and how/when they plan on including adults over the age of 21 and the type 1 population into their investigation.
Here is their response to us:
"Results from the TOPAZ trial will be used to inform and guide further development decisions for SRK-015, including future trials that may include a broader age group of adults and individuals with Type 1 SMA. We will continue our collaborative approach with updates surrounding progress and plans for the SRK-015 program, as results from the TOPAZ trial emerge and help guide the path forward"